BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Summary

This study aims to leverage this unique property of HPV+ OPC to detect possible minimal residual disease represented by persistent viral detection after the completion of definitive treatment. The study will offer adjuvant immune therapy to patients with persistent viral detection and evaluate the clearance of viral load. It will evaluate the rate of viral clearance with immune therapy and establish the link between viral clearance and long-term disease control.

Timeline

Start

2023-10-18

Primary completion

2026-05-04

Completion

2026-05-04

Drugs

Indications